Lineage Cell Therapeutics (LCTX) News Today → Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad) Free LCTX Stock Alerts $1.08 +0.02 (+1.89%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | markets.businessinsider.comBuy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid FinancialsMay 13, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Lineage Cell Therapeutics, Inc.'s FY2028 Earnings (NYSEAMERICAN:LCTX)May 10, 2024 | finance.yahoo.comQ1 2024 Lineage Cell Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue DeclinesMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | americanbankingnews.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Expected to Post FY2026 Earnings of $0.06 Per ShareMay 9, 2024 | businesswire.comLineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | marketbeat.comBrokers Set Expectations for Lineage Cell Therapeutics, Inc.'s FY2026 Earnings (NYSEAMERICAN:LCTX)Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a report issued on Monday, May 6th. HC Wainwright analyst J. Pantginis forecasts that the companyMay 8, 2024 | markets.businessinsider.comBuy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA PatientsMay 6, 2024 | markets.businessinsider.comMaintained Buy Rating for Lineage Cell Therapeutics on Robust Clinical Trial Results and Strong Partnership with RocheMay 6, 2024 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday.May 6, 2024 | businesswire.comOpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitMay 2, 2024 | businesswire.comLineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024April 30, 2024 | businesswire.comLineage Receives Grant From California Institute for Regenerative Medicine (CIRM)April 29, 2024 | businesswire.comLineage Announces Changes to Board of DirectorsApril 19, 2024 | finance.yahoo.com12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear ByApril 1, 2024 | finance.yahoo.comLineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentMarch 28, 2024 | msn.com5 Simple Wealth-Building Tips For This Generation's Forward-ThinkersMarch 19, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data ReleaseMarch 18, 2024 | seekingalpha.comPuma Biotechnology dips after dismissal of its suit was granted by a federal judgeMarch 18, 2024 | finance.yahoo.com15 Best Anti-Aging Foods for Youthful SkinMarch 18, 2024 | finance.yahoo.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumMarch 18, 2024 | businesswire.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumMarch 14, 2024 | finance.yahoo.comBillionaire Ken Fisher and Corporate Insiders Are Buying These 10 StocksMarch 13, 2024 | finance.yahoo.comRG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitMarch 11, 2024 | finance.yahoo.comRG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology MeetingMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy AdvancementsMarch 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic PartnershipsMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lineage Cell Therapeutics Amid Strong Financials and Promising OpRegen Therapy ResultsMarch 8, 2024 | insidermonkey.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.comLCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023March 7, 2024 | finance.yahoo.comLineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial ResultsMarch 7, 2024 | benzinga.comLineage Cell Therapeutics: Q4 Earnings InsightsMarch 7, 2024 | businesswire.comLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | benzinga.comA Preview Of Lineage Cell Therapeutics's EarningsFebruary 29, 2024 | finance.yahoo.comLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024February 14, 2024 | benzinga.comLineage Cell Therapeutics Stock (AMEX:LCTX), Analyst Ratings, Price Targets, PredictionsFebruary 13, 2024 | markets.businessinsider.comStrong Buy Rating for Lineage Therap Backed by Promising Developments in Spinal Cord Injury TherapyFebruary 13, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday.February 9, 2024 | finance.yahoo.comLineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct OfferingFebruary 9, 2024 | businesswire.comLineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct OfferingFebruary 7, 2024 | msn.comLineage Cell Therapeutics Secures $14M in Direct OfferingFebruary 6, 2024 | msn.comLineage Cell Therapeutics looks to raise $14M through direct offeringFebruary 6, 2024 | finance.yahoo.comLineage Cell Therapeutics Announces $14.0 Million Registered Direct OfferingFebruary 5, 2024 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given Overweight Rating at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $6.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday.January 16, 2024 | finance.yahoo.comRG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRSJanuary 3, 2024 | insidermonkey.comHedge Fund and Insider Trading News: David Tepper, Bill Ackman, Ken Griffin, Ricky Sandler, ValueAct Capital, Globalstar Inc (GSAT), Lineage Cell Therapeutics, Inc. (LCTX), and MoreDecember 19, 2023 | markets.businessinsider.comBuy Rating Affirmed for Lineage Cell Therapeutics Amid Promising Advances in Spinal Cord Injury TreatmentDecember 18, 2023 | finance.yahoo.comLineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord InjuryNovember 10, 2023 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address weirdest stock market marches on (Ad)For the last few months, Graham Lindman has been urging investors to ignore virtually every stock on the exchange and only focus on the handful of “Apex Stocks” that produce all the wealth. And he sure seems to be right! Because while we’re in an extremely bullish market, it’s not because most companies are doing that well. It’s because a handful of wealth generating juggernauts are yanking the market to all time highs. That’s why this headline called it the “Weirdest bull market” Graham is hosting a “tell all” workshop about his Apex Indicator here LCTX Media Mentions By Week LCTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LCTX News Sentiment▼0.010.42▲Average Medical News Sentiment LCTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LCTX Articles This Week▼51▲LCTX Articles Average Week Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Elevation Oncology News Fennec Pharmaceuticals News Kodiak Sciences News Century Therapeutics News Adverum Biotechnologies News INmune Bio News Genfit News Opthea News Compugen News Innate Pharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:LCTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin Analytics41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
